Exelixis, Inc. — Form 10-Q Summary
Business context and reporting period
Exelixis is an oncology-focused biotechnology company. Its principal commercial product is CABOMETYX (cabozantinib); it also markets COMETRIQ and receives collaboration revenue from other products and partnerships. The supplied filing is for the quarter ended July 2, 2021, with financial statements presented for the three and six months ended June 30, 2021. This conflicts with the request metadata identifying “2020 Q2”; the filing itself is for 2021 Q2. Filed August 5, 2021.
Financial performance and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Total revenue | $385.2 million | $259.5 million | $655.4 million | $486.4 million |
| Net product revenue | $284.2 million | $178.7 million | $511.5 million | $372.6 million |
| Operating income | $123.0 million | $75.5 million | $118.4 million | $128.3 million |
| Net income | $96.1 million | $66.8 million | $97.7 million | $115.4 million |
| Diluted EPS | $0.30 | $0.21 | $0.30 | $0.36 |
Q2 gross margin was 95%, unchanged year over year. Q2 R&D expense rose to $148.8 million from $114.9 million; SG&A rose to $98.5 million from $59.8 million. Six-month operating cash flow was $221.0 million, versus $157.8 million in 2020. Cash, cash equivalents, restricted cash and investments totaled $1.7 billion at June 30, 2021, up from $1.5 billion at December 31, 2020. Current assets were $1.59 billion and current liabilities $255.3 million. The balance sheet presents no debt balance; the filing reports no material off-balance-sheet arrangements.
Changes versus comparable periods
- Q2 total revenue increased 48%; net product revenue increased 59%, primarily reflecting CABOMETYX demand following FDA approval with OPDIVO as first-line treatment for advanced renal cell carcinoma (RCC) in January 2021.
- Q2 collaboration services revenue increased 185%, mainly from development-cost reimbursements, including Ipsen’s decision to co-fund COSMIC-311. License revenue decreased 33%, partly reflecting fewer milestone revenues than in 2020.
- Q2 net income increased 44%, while six-month net income fell to $97.7 million from $115.4 million. For the six-month period, higher R&D and SG&A costs and lower license revenue outweighed revenue growth.
- Interest income declined 63% in both the quarter and six-month comparison, primarily because of lower interest rates.
Outlook, commentary, risks and unusual items
- Management expects net product revenue for the remainder of 2021 may increase year over year, citing CABOMETYX/OPDIVO demand and a CABOMETYX price increase; discounts and allowances as a share of gross revenue may also rise. It expects fewer milestone revenues in 2021, partly offset by royalty growth, and potentially higher collaboration services revenue and R&D and SG&A expenses. No full-year numerical revenue or earnings guidance is provided.
- The company reported COSMIC-312 met its progression-free-survival endpoint for cabozantinib plus atezolizumab versus sorafenib in previously untreated advanced liver cancer, but interim overall-survival results did not reach statistical significance. Management said the trial would continue to final OS analysis, anticipated in early 2022, while noting a low probability of statistical significance at final analysis.
- The FDA accepted the CABOMETYX supplemental application for radioactive iodine-refractory differentiated thyroid cancer (DTC), granted Priority Review, and set a December 4, 2021 target action date; this was announced after quarter-end. Ipsen opted into co-funding COSMIC-311, resulting in a cumulative catch-up of collaboration services revenue.
- Management described COVID-19 effects as modest at the time of filing, but warned renewed outbreaks or variants could disrupt trials, enrollment, operations or supply. Other key risks include clinical and regulatory uncertainty, pricing and reimbursement pressure, dependence on CABOMETYX and collaboration partners, and potential generic competition.
- Generic-entry litigation is pending against MSN, with a bench trial scheduled for May 2022, and against Teva. The company says early generic CABOMETYX sales could materially reduce U.S. revenue; potential losses cannot currently be estimated.
- Pipeline business-development arrangements included $17.0 million of aggregate upfront payments and potential future milestones and royalties; a GamaMabs asset purchase included a $5.0 million upfront payment and a conditional additional $9.0 million payment.
Most important facts for investors to verify
- Confirm the reporting period: the request says 2020 Q2, but the filing and financial comparisons concern 2021 Q2.
- Track CABOMETYX demand, discount and rebate levels, and the revenue contribution from the RCC combination launch.
- Review final COSMIC-312 overall-survival results and the regulatory outcome and commercial potential for the DTC application.
- Monitor MSN and Teva patent proceedings and verify the patent-number references: the filing contains a 9,724,342/9,724,324 discrepancy in its Teva discussion.
- Assess whether rising R&D and SG&A spending, business-development commitments and collaboration reimbursements are sustainable relative to operating cash generation.